secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-08-12T12:18:05+00:00
Accession:  0001628280-26-055962
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal expands board to nine, appoints J&J R&D chief John C. Reed
-------------------------------------------------------------------

- Board grew from 8 to 9 members; Reed elected Class II director, term to 2027 annual meeting.
- Reed is EVP Innovative Medicine R&D at Johnson & Johnson, leading oncology, immunology, neuroscience research.
- Compensation: $50k cash retainer, $10k for Science & Tech Committee, $675k equity grant (50% options, 50% RSUs).
- Reed joins Science and Technology Committee; no material transactions disclosed under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/0001628280-26-055962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/mdgl-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-055962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer